International Consensus Group

These are some of the highlights of the guidelines without analysis or commentary. For more information, go directly to the guidelines by clicking the link in the reference.

December 04, 2024

1

41

Share

Added to Email Alerts

A clinical guideline update on the management of diabetes as well as cardiorenal and metabolic diseases (DCRM) was published in June 2024 by an international consensus group of cardiologists, nephrologists, endocrinologists, and primary care physicians, in Metabolism: Clinical and Experimental.^[1]

With regard to patient education, the patient’s priorities should be determined; early, aggressive treatment should be emphasized; open-ended questions should be asked; and the patient’s personal challenges and goals should be affirmed, with the patient encouraged in the belief that he or she can control his or her health outcomes.

With regard to the use of technology and digital care, validated apps and wearables should be employed to track factors such as weight, calorie intake, nutritional quality, physical activity, blood pressure, heart rate, and sleep quality.

Prior to the onset of cognitive dysfunction, risk factors—including insulin resistance, hypertension, obesity, hyperlipidemia, hyperglycemia, hypoglycemia, and hearing loss—should be managed/treated. Regular screening for cognitive impairment, beginning with a dementia risk score, should be performed.

Clinical assessment of patients with obesity should include evaluation for diseases and disease risk factors related to obesity, as well as for physical function, quality of life, mental health and eating disorders, weight history, barriers to lifestyle change and weight-loss treatment, and personal weight/health goals (along with reasons for those goals). Lifestyle factors such as diet, eating behaviors, daily physical activities, sleep, work factors, and family/social support, should also be assessed.

With regard to lipid disorders, until the individual lipid target is met, lipids should be monitored every 6-12 weeks. Low-density–lipoprotein cholesterol should be decreased by 50% or more or reduced to the risk-based goal, whichever is lower.

For more information, please go to Type 2 Diabetes Mellitus, Obesity, Heart Failure, Pediatric Lipid Disorders in Clinical Practice, Chronic Kidney Disease (CKD), and Hypertension.

• 1
• 41